Our solid orals portfolio comprises of immediate release & complex modified release formulations.
- 26 Solid Orals launched in US & 20 Solid Orals under development or ongoing Pilot/Pivotal bioequivalence studies. These are marketed through our US affiliate Indicus Pharma. To know more please visit: www.indicuspharma.com
- 12 Solid Orals launched in Europe and 10 solid oral dossiers are on offer for EU market. 22 solid orals under development or ongoing Pilot/Pivotal bioequivalence studies. These are marketed through our EU subsidiary JUTA Pharma. To know more please visit: www.jutapharma.de
These are manufactured at our cGMP compliant plants in India which are ISO 14001 and OHSAS 18001 certified.
For more information about our existing portfolio and our pipeline products please e-mail us at email@example.com